Cross-Over Boceprevir Treatment — Competitive Intelligence Brief

Cross-Over Boceprevir Treatment (Cross-Over Boceprevir Treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HCV NS3 protease inhibitor. Area: Virology / Hepatology.

phase 3 HCV NS3 protease inhibitor HCV NS3/4A serine protease Virology / Hepatology Small molecule

Target snapshot

Cross-Over Boceprevir Treatment (Cross-Over Boceprevir Treatment) — Merck Sharp & Dohme LLC. Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral replication by preventing the cleavage of HCV polyproteins.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cross-Over Boceprevir Treatment TARGET	Cross-Over Boceprevir Treatment	Merck Sharp & Dohme LLC	phase 3	HCV NS3 protease inhibitor	HCV NS3/4A serine protease
Elbasvir/Grazoprevir	Elbasvir/Grazoprevir	University of Florence	marketed	Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor	HCV NS5A protein and HCV NS3/4A serine protease
Viekira Pak ± ribavirin	Viekira Pak ± ribavirin	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein, HCV NS3/4A serine protease
Elbasvir / Grazoprevir Oral Tablet [Zepatier]	Elbasvir / Grazoprevir Oral Tablet [Zepatier]	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS3/4A serine protease
Daclatasvir plus Asunaprevir	Daclatasvir plus Asunaprevir	Myeong Jun Song	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease
ABT-450/ritonavir	ABT-450/ritonavir	AbbVie (prior sponsor, Abbott)	phase 3	Hepatitis C virus NS3/4A protease inhibitor	HCV NS3/4A serine protease
Elbasvir/Grazoprevir Fixed Dose Combination	Elbasvir/Grazoprevir Fixed Dose Combination	University Hospital, Clermont-Ferrand	phase 3	HCV direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HCV NS3 protease inhibitor class)

1. Merck Sharp & Dohme LLC · 2 drugs in this class
2. Bristol-Myers Squibb · 1 drug in this class